Study EV-302: A two-arm, open-label, randomized controlled phase 3 study of enfortumab vedotin in combination with pembrolizumab versus chemotherapy in previously untreated advanced urothelial carcinoma (aUC) (trial in progress).

被引：12
|
作者：
Van der Heijden, Michiel Simon
Gupta, Shilpa
Galsky, Matt D.
Derleth, Christina Louise
Lee, Sue
Kataria, Ritesh S.
Powles, Thomas
机构：
[1] Netherlands Canc Inst, Amsterdam, Netherlands
[2] Cleveland Clin Fdn, Taussig Canc Inst, Cleveland, OH USA
[3] Icahn Sch Med Mt Sinai, Tisch Canc Inst, Div Hematol & Med Oncol, New York, NY USA
[4] Seagen Inc, Bothell, WA USA
[5] Astellas Pharma Inc, Northbrook, IL USA
[6] Merck & Co Inc, Kenilworth, NJ USA
[7] Queen Mary Univ London, Barts Canc Inst, Canc Res UK Expt Canc Med Ctr, London, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 06期
关键词：
D O I：
10.1200/JCO.2022.40.6_suppl.TPS589
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS589
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Study EV-103 Cohort K: Antitumor activity of enfortumab vedotin (EV) monotherapy or in combination with pembrolizumab (P) in previously untreated cisplatin-ineligible patients (pts) with locally advanced or metastatic urothelial cancer (la/mUC)
    Rosenberg, J. E.
    Milowsky, M.
    Ramamurthy, C.
    Mar, N.
    Mckay, R. R.
    Friedlander, T.
    Ferrario, C.
    Bracarda, S.
    George, S.
    Moon, H.
    Geynisman, D.
    Petrylak, D. P.
    Borchiellini, D.
    Burgess, E. F.
    Rey, J. P. Maroto
    Carret, A-S.
    Yu, Y.
    Guseva, M. V.
    Moreno, B. Homet
    O'Donnell, P. H.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1441 - S1441
  • [32] EV-301 Long-Term Outcomes: 24-Month Findings From Phase 3 Trial of Enfortumab Vedotin vs Chemotherapy in Previously Treated Advanced Urothelial Carcinoma
    Rosenberg, J.
    Powles, T.
    Sonpavde, G.
    Loriot, Y.
    Duran, I.
    Lee, J.
    Matsubara, N.
    Vulsteke, C.
    Castellano, D.
    Mamtani, R.
    Wu, C.
    Matsangou, M.
    Campbell, M.
    Petrylak, D.
    Cathomas, R.
    SWISS MEDICAL WEEKLY, 2022, 152 : 16S - 17S
  • [33] EV-301 long-term outcomes: 24-month findings from the phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma
    Rosenberg, J. E.
    Powles, T.
    Sonpavde, G. P.
    Loriot, Y.
    Duran, I.
    Lee, J. -L.
    Matsubara, N.
    Vulsteke, C.
    Castellano, D.
    Mamtani, R.
    Wu, C.
    Matsangou, M.
    Campbell, M.
    Petrylak, D. P.
    ANNALS OF ONCOLOGY, 2023, 34 (11) : 1047 - 1054
  • [34] EV-202: An open-label, multicenter, phase 2 study of enfortumab vedotin in patients with previously treated locally advanced or metastatic solid tumors, including upper gastrointestinal cancers
    Muro, K.
    Bruce, J.
    Baranda, J.
    Gorla, S.
    Wu, C.
    Braiteh, F.
    ANNALS OF ONCOLOGY, 2021, 32 : S130 - S130
  • [35] A phase 3, randomized, open-label study of nivolumab combined with ipilimumab versus sunitinib monotherapy in subjects with previously untreated metastatic renal cell carcinoma
    Hammers, H.
    Sternberg, C.
    Mcdermott, D. F.
    Larkin, J.
    Ravaud, A.
    Rini, B.
    Sharma, P.
    Bhagavatheeswaran, P.
    Gagnier, P.
    Motzer, R.
    BJU INTERNATIONAL, 2014, 114 : 9 - 9
  • [36] KEYNOTE-045: OPEN-LABEL, PHASE 3 STUDY OF PEMBROLIZUMAB VERSUS INVESTIGATOR'S CHOICE OF PACLITAXEL, DOCETAXEL, OR VINFLUNINE FOR PREVIOUSLY TREATED ADVANCED UROTHELIAL CANCER
    Quinn, David
    Bellmunt, Joaquim
    De Wit, Ronald
    Vaughn, David J.
    Fradet, Yves
    Lee, Jae Lyun
    Fong, Lawrence
    Vogelzang, Nicholas J.
    Climent, Miguel A.
    Petrylak, Daniel P.
    Choueiri, Toni K.
    Necchi, Andrea
    Gerritsen, Winald
    Gurney, Howard
    Culine, Stephane
    Sternberg, Cora N.
    Mai, Yabing
    Puhlmann, Markus
    Perini, Rodolfo F.
    Bajorin, Dean F.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017, 13 : 35 - 35
  • [37] Open-label, phase I/randomized, phase II trial of the triple angiokinase inhibitor, nintedanib, versus sorafenib in previously untreated patients with advanced hepatocellular carcinoma (HCC)
    Palmer, Daniel H.
    Peck-Radosavljevic, Markus
    Ma, Yuk Ting
    Graham, Janet
    Fartoux, Laetitia
    Hubner, Richard
    Loembe, Arsene Bienvenu
    Studeny, Matus
    Hocke, Julia
    Meyer, Tim
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [38] Efficacy and safety of sintilimab in combination with chemotherapy in previously untreated advanced or metastatic nonsquamous or squamous NSCLC: two cohorts of an open-label, phase 1b study
    Jiang, Haiping
    Zheng, Yulong
    Qian, Jiong
    Mao, Chenyu
    Xu, Xin
    Li, Ning
    Xiao, Cheng
    Wang, Huan
    Teng, Lisong
    Zhou, Hui
    Wang, Shuyan
    Zhu, Donglei
    Sun, Tao
    Yu, Yingying
    Guo, Wenying
    Xu, Nong
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2021, 70 (03) : 857 - 868
  • [39] Efficacy and safety of sintilimab in combination with chemotherapy in previously untreated advanced or metastatic nonsquamous or squamous NSCLC: two cohorts of an open-label, phase 1b study
    Haiping Jiang
    Yulong Zheng
    Jiong Qian
    Chenyu Mao
    Xin Xu
    Ning Li
    Cheng Xiao
    Huan Wang
    Lisong Teng
    Hui Zhou
    Shuyan Wang
    Donglei Zhu
    Tao Sun
    Yingying Yu
    Wenying Guo
    Nong Xu
    Cancer Immunology, Immunotherapy, 2021, 70 : 857 - 868
  • [40] Re: EV-301 Long-term Outcomes: 24-month Findings from the Phase III Trial of Enfortumab Vedotin Versus Chemotherapy in Patients with Previously Treated Advanced Urothelial Carcinoma
    Drake, Marcus J.
    Birder, Lori A.
    EUROPEAN UROLOGY, 2024, 86 (02) : 183 - 184
12345